Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01217450 · ClinicalTrials.gov registry record · Phase 1
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01217450: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01217450 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01217450, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and the best dose of MEK Inhibitor AZD6244 when given together with cetuximab in patients with advanced or refractory solid tumors that cannot be removed by surgery. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving MEK Inhibitor AZD6244 together with cetuximab may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL cetuximab
- OTHER pharmacological study
- DRUG selumetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01217450
The ClinicalTrials.gov registry entry for NCT01217450 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01217450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01217450 about?
NCT01217450 is a clinical study titled "Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors". This phase I trial is studying the side effects and the best dose of MEK Inhibitor AZD6244 when given together with cetuximab in patients with advanced or refractory solid tumors that cannot be removed by surgery. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzym...
What is the current status of trial NCT01217450?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2012-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01217450?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cetuximab (BIOLOGICAL), pharmacological study (OTHER), selumetinib (DRUG).
Who is sponsoring clinical trial NCT01217450?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.